Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

Autor: R.K. Agrawal, R Cf Leonard, Elena Provenzano, Peter Simmonds, Sarah Jordan, S M Crawford, Robert Grieve, S. Bathers, David Cameron, Carlos Caldas, J Ms Bartlett, Fiona M. Blows, D.W. Rea, Louise Hiller, I. N. Fernando, Karen McAdam, Sarah Bowden, P Pharoah, Janine Mansi, Helena M. Earl, David Spooner, Janet A. Dunn, Alison F. Munro, Andrew Stanley, L. Foster, Chris J. Twelves, S O'Reilly, Christopher J. Poole, A.M. Brunt, A-L Vallier

Publikováno v: British Journal of Cancer
Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R C F, Twelves, C J, Cameron, D, Bartlett, J M S, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J 2012, ' Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials ', British Journal of Cancer, vol. 107, no. 8, pp. 1257-1267 . https://doi.org/10.1038/bjc.2012.370

Background:\ud The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00a1b6ab9c6c1ed53cf274faa0f92266
https://eprints.keele.ac.uk/3177/1/bjc2012370a.pdf